Clinical Trial Update: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating transition from subcutaneous interferon therapy to peginterferon beta-1a (BIIB017) in relapsing multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Interferon beta-1a (Interferon beta-1a)
• Plegridy (Peginterferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: WITHDRAWN